-
1
-
-
0002035130
-
Metabolism of amphetamine and other arylisopropylamines
-
Cho AK, Segal DS, eds, San Diego, CA: Academic Press;
-
Cho AR, Kumangai Y. Metabolism of amphetamine and other arylisopropylamines. In: Cho AK, Segal DS, eds. Amphetamine and Its Analogs. San Diego, CA: Academic Press; 1994:43-77.
-
(1994)
Amphetamine and Its Analogs
, pp. 43-77
-
-
Cho, A.R.1
Kumangai, Y.2
-
2
-
-
0029916656
-
Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion
-
Chu T, Kumagai Y, DiStefano EW, et al. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol. 1996;51:789-796.
-
(1996)
Biochem Pharmacol
, vol.51
, pp. 789-796
-
-
Chu, T.1
Kumagai, Y.2
DiStefano, E.W.3
-
3
-
-
4143152622
-
Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition
-
de la Torre R, Farre M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004; 26:137-144.
-
(2004)
Ther Drug Monit
, vol.26
, pp. 137-144
-
-
de la Torre, R.1
Farre, M.2
Roset, P.N.3
-
4
-
-
47249166411
-
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults
-
Kolbrich EA, Goodwin RS, Gorelick DA, et al. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. 2008;30: 320-332.
-
(2008)
Ther Drug Monit
, vol.30
, pp. 320-332
-
-
Kolbrich, E.A.1
Goodwin, R.S.2
Gorelick, D.A.3
-
5
-
-
0028292728
-
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy"): Pharmacology and toxicology in animals and humans
-
Steele TD, McCann UD, Ricaurte GA.3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 1994;89:539-551.
-
(1994)
Addiction
, vol.89
, pp. 539-551
-
-
Steele, T.D.1
McCann, U.D.2
Ricaurte, G.A.3
-
6
-
-
0041466261
-
The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")
-
Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003;55:463-508.
-
(2003)
Pharmacol Rev
, vol.55
, pp. 463-508
-
-
Green, A.R.1
Mechan, A.O.2
Elliott, J.M.3
-
7
-
-
51849123181
-
Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/2)3,4-methylenedioxymethamphetamine ("ecstasy") users: Relationship to cognitive performance
-
McCann UD, Szabo Z, Vranesic M, et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/2)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl). 2008; 200:439-450.
-
(2008)
Psychopharmacology (Berl)
, vol.200
, pp. 439-450
-
-
McCann, U.D.1
Szabo, Z.2
Vranesic, M.3
-
8
-
-
52649087879
-
Nonlinear pharmacokinetics of (+/2)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses
-
Mueller M, Peters FT, Maurer HH, et al. Nonlinear pharmacokinetics of (+/2)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J Pharmacol Exp Ther. 2008;327:38-44.
-
(2008)
J Pharmacol Exp Ther
, vol.327
, pp. 38-44
-
-
Mueller, M.1
Peters, F.T.2
Maurer, H.H.3
-
9
-
-
0002209037
-
The use of interspecies scaling in toxicokinetics
-
Yacobi A, Kelly J, Batra V, eds, New York, NY: Pergamon Press;
-
Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V, eds. Toxicokinetics in New Drug Development. New York, NY: Pergamon Press; 1989:42-96.
-
(1989)
Toxicokinetics in New Drug Development
, pp. 42-96
-
-
Mordenti, J.1
Chappell, W.2
-
10
-
-
58249136270
-
Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage
-
Mueller M, Peters FT, Huestis MA, et al. Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage. Forensic Sci Int. 2009; 184:64-68.
-
(2009)
Forensic Sci Int
, vol.184
, pp. 64-68
-
-
Mueller, M.1
Peters, F.T.2
Huestis, M.A.3
-
11
-
-
30944431901
-
Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons
-
Mechan A, Yuan J, Hatzidimitriou G, et al. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology. 2006;31:339-350.
-
(2006)
Neuropsychopharmacology
, vol.31
, pp. 339-350
-
-
Mechan, A.1
Yuan, J.2
Hatzidimitriou, G.3
-
12
-
-
0033967676
-
Non-linear pharmacokinetics of MDMA (-ecstasy-) in humans
-
de la Torre R, Farre M, Ortuno J, et al. Non-linear pharmacokinetics of MDMA (-ecstasy-) in humans. Br J Clin Pharmacol. 2000;49:104-109.
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 104-109
-
-
de la Torre, R.1
Farre, M.2
Ortuno, J.3
-
13
-
-
0028178550
-
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6)
-
Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151-1156.
-
(1994)
Biochem Pharmacol
, vol.47
, pp. 1151-1156
-
-
Tucker, G.T.1
Lennard, M.S.2
Ellis, S.W.3
-
14
-
-
0037096036
-
Reduced (+/2)-3,4- methylenedioxymethamphetamine ("ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro
-
Ramamoorthy Y, Yu AM, Suh N, et al. Reduced (+/2)-3,4- methylenedioxymethamphetamine ("ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol. 2002;63:2111-2119.
-
(2002)
Biochem Pharmacol
, vol.63
, pp. 2111-2119
-
-
Ramamoorthy, Y.1
Yu, A.M.2
Suh, N.3
-
15
-
-
33750368923
-
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA
-
Yang J, Jamei M, Heydari A, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol. 2006;20:842-849.
-
(2006)
J Psychopharmacol
, vol.20
, pp. 842-849
-
-
Yang, J.1
Jamei, M.2
Heydari, A.3
-
16
-
-
54349126394
-
The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxymethamphetamine and its enantiomers
-
Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxymethamphetamine and its enantiomers. Drug Metab Dispos. 2008;36: 2345-2354.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 2345-2354
-
-
Meyer, M.R.1
Peters, F.T.2
Maurer, H.H.3
-
17
-
-
4143053372
-
The role of metabolism in 3,4-(+)- methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity
-
Monks T, Jones D, Bai F, et al. The role of metabolism in 3,4-(+)- methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit. 2004;26:132-136.
-
(2004)
Ther Drug Monit
, vol.26
, pp. 132-136
-
-
Monks, T.1
Jones, D.2
Bai, F.3
-
18
-
-
37349127647
-
Accumulation of neurotoxic thioether metabolites of 3,4-(+/2)-methylenedioxymethamphetamine in rat brain
-
Erives GV, Lau SS, Monks TJ. Accumulation of neurotoxic thioether metabolites of 3,4-(+/2)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther. 2008;324:284-291.
-
(2008)
J Pharmacol Exp Ther
, vol.324
, pp. 284-291
-
-
Erives, G.V.1
Lau, S.S.2
Monks, T.J.3
-
19
-
-
0034812738
-
3, 4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans
-
Segura M, Ortuño J, Farré M, et al. 3, 4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol. 2001;14:1203-1208.
-
(2001)
Chem Res Toxicol
, vol.14
, pp. 1203-1208
-
-
Segura, M.1
Ortuño, J.2
Farré, M.3
|